

Appl. No. : 09/991,433
Filed : November 16, 2001

AMENDMENTS TO THE CLAIMS

1. - 43 (Previously cancelled)

44. **(Currently Amended)** A method of inhibiting hematopoiesis comprising:
contacting a plurality of hematopoietic cells with an inhibiting amount of a B19
parvovirus capsid agent comprising the sequence glutamine-glutamine-tyrosine; and
measuring the inhibition of hematopoiesis.

45. **(Currently Amended)** The method of Claim 44 wherein the capsid agent comprises the
VP1 and VP2 proteins.

46. **(Currently Amended)** The method of Claim 44, wherein the capsid agent comprises the
VP2 protein.

47. **(Previously Presented)** The method of Claim 44, wherein the capsid agent comprises a
sequence selected from the group consisting of SEQ. ID NO. 2, SEQ. ID. NO. 3, SEQ. ID.
NO. 4, SEQ. ID. NO. 5, SEQ. ID. NO. 6, SEQ. ID. NO. 7, SEQ. ID. NO. 8, and SEQ. ID.
NO. 48.

48. **(Previously Presented)** The method of Claim 44, wherein the capsid agent consists of the
sequence glutamine-glutamine-tyrosine.

49. **(Previously Presented)** The method of Claim 47, wherein the sequence is SEQ. ID. NO. 2.

50. **(Previously Presented)** The method of Claim 47, wherein the sequence is SEQ. ID. NO. 3.

51. **(Previously Presented)** The method of Claim 47, wherein the sequence is SEQ. ID. NO. 4.

52. **(Previously Presented)** The method of Claim 47, wherein the sequence is SEQ. ID. NO. 5.

53. **(Previously Presented)** The method of Claim 47, wherein the sequence is SEQ. ID. NO. 6.

54. **(Previously Presented)** The method of Claim 47, wherein the sequence is SEQ. ID. NO. 7.

55. **(Previously Presented)** The method of Claim 47, wherein the sequence is SEQ. ID. NO. 8.

56. **(Previously Presented)** The method of Claim 47, wherein the sequence is SEQ. ID. NO.
48.

57. **(Currently Amended)** The method of Claim 44, wherein the capsid agent comprises the
VP1 protein.

Appl. No. : 09/991,433
Filed : November 16, 2001

58. (Cancelled)

59. (Currently Amended) A method of inhibiting hematopoiesis comprising:
identifying a subject in need of an inhibition of hematopoiesis; and
providing to said subject an inhibiting amount of a B19 parvovirus capsid agent
comprising the sequence glutamine-glutamine-tyrosine.

60. (Currently Amended) The method of Claim 59, wherein the capsid agent comprises the
VP1 and VP2 proteins.

61. (Currently Amended) The method of Claim 59, wherein the capsid agent comprises the
VP2 protein.

62. (Previously Presented) The method of Claim 59, wherein the capsid agent comprises a
sequence selected from the group consisting of SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ.
ID. NO. 4, SEQ. ID. NO. 5, SEQ. ID. NO. 6, SEQ. ID. NO. 7, SEQ. ID. NO. 8, and SEQ.
ID. NO. 48.

63. (Previously Presented) The method of Claim 59, wherein the capsid agent consists of the
sequence glutamine-glutamine-tyrosine.

64. (Previously Presented) The method of Claim 59, wherein the sequence is SEQ. ID. NO. 2.

65. (Previously Presented) The method of Claim 59, wherein the sequence is SEQ. ID. NO. 3.

66. (Previously Presented) The method of Claim 59, wherein the sequence is SEQ. ID. NO. 4.

67. (Previously Presented) The method of Claim 59, wherein the sequence is SEQ. ID. NO. 5.

68. (Previously Presented) The method of Claim 59, wherein the sequence is SEQ. ID. NO. 6.

69. (Previously Presented) The method of Claim 59, wherein the sequence is SEQ. ID. NO. 7.

70. (Previously Presented) The method of Claim 59, wherein the sequence is SEQ. ID. NO. 8.

71. (Previously Presented) The method of Claim 59, wherein the sequence is SEQ. ID. NO.
48.

72. (Previously Presented) The method of Claim 59, wherein the subject has a hematological
proliferative disorder.

73. (Previously Presented) The method of Claim 72, wherein the hematological proliferative
disorder is polycythemia vera.

74. (Cancelled)